PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
12.50%
Gross profit growth of 12.50% while RVPH is zero. Bruce Berkowitz would see if minimal improvements could expand further.
-29.39%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-29.39%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-30.95%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-22.58%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-22.58%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
7.95%
Share count expansion well above RVPH's 2.23%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.95%
Diluted share count expanding well above RVPH's 2.23%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-8.11%
Negative OCF growth while RVPH is at 27.71%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-7.95%
Negative FCF growth while RVPH is at 27.71%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while RVPH stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.14%
OCF/share CAGR of 91.14% while RVPH is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
75.06%
Positive OCF/share growth while RVPH is negative. John Neff might see a comparative advantage in operational cash viability.
-16.88%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-109.23%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
62.10%
Positive 5Y CAGR while RVPH is negative. John Neff might view this as a strong mid-term relative advantage.
-51.96%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-71.08%
Negative equity/share CAGR over 10 years while RVPH stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-53.15%
Negative 5Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-63.40%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.71%
Positive asset growth while RVPH is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-7.41%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-6.71%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
37.48%
We increase R&D while RVPH cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
21.30%
SG&A growth well above RVPH's 19.04%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.